公开(公告)号：US20240254221A1

公开(公告)日：2024-08-01

申请号：US18383043

申请日：2023-10-23

Applicant: Singapore Health Services PTE LTD ,  Agency for Science, Technology and Research

Inventor： Hau Wan LEUNG ,  Andre Boon Hwa Choo ,  Mei Yee Vanessa Ding ,  Shao Weng Daniel Tan ,  Narayanan Gopalakrishna Iyer

IPC: C07K16/28 ,  A61K39/00 ,  A61K47/64 ,  A61K47/68 ,  A61K51/10 ,  A61P35/00 ,  C07K16/30 ,  C07K16/44 ,  G01N33/574

CPC classification number: C07K16/2803 ,  A61K47/6415 ,  A61K47/6857 ,  A61K51/1048 ,  A61P35/00 ,  C07K16/30 ,  C07K16/44 ,  G01N33/57473 ,  A61K2039/505 ,  A61K2039/55 ,  C07K2317/732

Abstract: The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof which binding to CEACAM6, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GNTFTSYVMH; a VHCDR2 having the amino acid sequence YINPYNDGTKYNEKFKG; and a VHCDR3 having the amino acid sequence STARATPYFYAMDY and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLWSVNQNSYLS, a VLCDR2 having the amino acid sequence GASIRES, and a VLCDR3 having the amino acid sequence QHNHGSFLPYT. The present invention also relates to compositions comprising the antigen-binding protein, or antigen-binding fragment thereof, methods of use of the antigen-binding protein, or antigen-binding fragment thereof for cancer treatment, prevention or detection and a kit comprising the antigen-binding protein, or antigen-binding fragment thereof.

公开(公告)号：US11236160B2

公开(公告)日：2022-02-01

申请号：US16341052

申请日：2017-10-10

Applicant: Singapore Health Services PTE LTD ,  AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Hau Wan Leung ,  Andre Boon Hwa Choo ,  Mei Yee Vanessa Ding ,  Shao Weng Daniel Tan ,  Narayanan Gopalakrishna Iyer

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/574 ,  A61K47/64 ,  A61K47/68 ,  C07K16/44 ,  A61K51/10 ,  C07K16/30 ,  A61K39/00

Abstract: The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof which binding to CEACAM6, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GNTFTSYVMH; a VHCDR2 having the amino acid sequence YINPYNDGTKYNEKFKG; and a VHCDR3 having the amino acid sequence STARATPYFYAMDY and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLWSVNQNSYLS, a VLCDR2 having the amino acid sequence GASIRES, and a VLCDR3 having the amino acid sequence QHNHGSFLPYT. The present invention also relates to compositions comprising the antigen-binding protein, or antigen-binding fragment thereof, methods of use of the antigen-binding protein, or antigen-binding fragment thereof for cancer treatment, prevention or detection and a kit comprising the antigen-binding protein, or antigen-binding fragment thereof.

公开(公告)号：US12227570B2

公开(公告)日：2025-02-18

申请号：US18383043

申请日：2023-10-23

Applicant: Singapore Health Services PTE LTD ,  AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Hau Wan Leung ,  Andre Boon Hwa Choo ,  Mei Yee Vanessa Ding ,  Shao Weng Daniel Tan ,  Narayanan Gopalakrishna Iyer

IPC: C07K16/28 ,  A61K39/00 ,  A61K47/64 ,  A61K47/68 ,  A61K51/10 ,  A61P35/00 ,  C07K16/30 ,  C07K16/44 ,  G01N33/574

Abstract: The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof which binding to CEACAM6, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GNTFTSYVMH; a VHCDR2 having the amino acid sequence YINPYNDGTKYNEKFKG; and a VHCDR3 having the amino acid sequence STARATPYFYAMDY and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLWSVNQNSYLS, a VLCDR2 having the amino acid sequence GASIRES, and a VLCDR3 having the amino acid sequence QHNHGSFLPYT. The present invention also relates to compositions comprising the antigen-binding protein, or antigen-binding fragment thereof, methods of use of the antigen-binding protein, or antigen-binding fragment thereof for cancer treatment, prevention or detection and a kit comprising the antigen-binding protein, or antigen-binding fragment thereof.

公开(公告)号：US11306153B2

公开(公告)日：2022-04-19

申请号：US16303657

申请日：2017-05-22

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Mei Yee Vanessa Ding ,  Boon Hwa Andre Choo ,  Wey Jia Fong

IPC: C07K16/40 ,  A61K47/68 ,  A61P35/00 ,  A61K39/00 ,  C07K19/00

Abstract: The present invention relates to antigen-binding proteins, or antigen-binding fragments thereof that bind to a glycan on the AXL receptor tyrosine kinase. The present invention also relates to antigen-binding proteins, or antigen-binding fragment conjugated to a radioisotope or cytotoxin, and wherein said antigen-binding proteins, or antigen-binding fragment is internalised into a cell upon binding to AXL receptor tyrosine kinase. Compositions comprising a physiologically acceptable carrier and a therapeutically effective amount of the antigen-binding protein, or antigen-binding fragment thereof, therapeutic use of the antigen-binding protein, or antigen-binding fragment thereof, methods for detecting cancer as well as kits when used in such methods are also provided.

公开(公告)号：US11820821B2

公开(公告)日：2023-11-21

申请号：US17560232

申请日：2021-12-22

Applicant: Singapore Health Services PTE LTD ,  AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Hau Wan Leung ,  Andre Boon Hwa Choo ,  Mei Yee Vanessa Ding ,  Shao Weng Daniel Tan ,  Narayanan Gopalakrishna Iyer

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/574 ,  A61K47/64 ,  A61K47/68 ,  C07K16/44 ,  A61K51/10 ,  C07K16/30 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K47/6415 ,  A61K47/6857 ,  A61K51/1048 ,  A61P35/00 ,  C07K16/30 ,  C07K16/44 ,  G01N33/57473 ,  A61K2039/505 ,  A61K2039/55 ,  C07K2317/732

Abstract: The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof which binding to CEACAM6, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GNTFTSYVMH; a VHCDR2 having the amino acid sequence YINPYNDGTKYNEKFKG; and a VHCDR3 having the amino acid sequence STARATPYFYAMDY and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLWSVNQNSYLS, a VLCDR2 having the amino acid sequence GASIRES, and a VLCDR3 having the amino acid sequence QHNHGSFLPYT. The present invention also relates to compositions comprising the antigen-binding protein, or antigen-binding fragment thereof, methods of use of the antigen-binding protein, or antigen-binding fragment thereof for cancer treatment, prevention or detection and a kit comprising the antigen-binding protein, or antigen-binding fragment thereof.

公开(公告)号：US10287547B2

公开(公告)日：2019-05-14

申请号：US15303520

申请日：2014-04-11

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH ,  SINGAPORE HEALTH SERVICES PTE LTD

Inventor： Mei Yee Vanessa Ding ,  Boon Hwa Andre Choo ,  Chui Ping Angela Chin ,  Jodhbir Singh Mehta ,  Gary Peh

IPC: C12N5/12 ,  C12N5/079 ,  C07K16/28 ,  C07K16/18 ,  C07K16/40

Abstract: This invention refers to an antibody or an antigen binding portion thereof, that binds specifically to human corneal endothelial cells (hCENCs), wherein the target of the monoclonal antibody, or antigen binding portion thereof, is essentially cell surface-expressed Peroxiredoxin-6 (Prdx6), as well as to methods for determining suitability of a cell sample for corneal transplantation, for quantitative enrichment of human corneal endothelial cells from a mixture of cells, and for isolating human corneal endothelial cells from a mixture of cell.